Life Sciences

Amgen brochure misleading, FDA warns

Pharma Compliance Alert, November 5, 2008

Amgen’s direct-to-consumer patient brochure for Senispar tablets improperly omits and minimizes risks associated with the drug and broadens its uses, according to an FDA warning letter.

The brochure completely omits one serious side effect of Senispar and fails to disclose any of the serious risks associated with the drug. In addition, Amgen minimizes the need for continual blood testing for patients taking Senispar.

The brochure also improperly emphasizes the benefits by using an easy to read layout over several pages but presents warnings and risks in a single paragraph on the back cover of the brochure. Pharmaceutical companies are required to provide a balanced presentation of risk and benefit information.

Amgen also broadened the use of Senispar by failing to communicate the drug’s full approved indication, including material limitations, according to the FDA.

The agency requested Amgen stop distributing the brochure and provide the FDA with a list of all promotional materials similar to the Senispar brochure and explain how it plans to discontinue use of such materials.

Comments

0 comments on “Amgen brochure misleading, FDA warns

 

    Healthcare Life Safety Compliance
  • Healthcare Life Safety Compliance

    Created exclusively for healthcare facility managers, plant operations professionals, and directors of engineering, this...

  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Complete Guide to Lab Safety, 3rd Ed.

    The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...

Most Popular